Quick Answer
Acurx Pharmaceuticals, Inc. reported Operating Income Loss of -$8.09 million for the year ending 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +42.7% in Operating Income Loss from 2024 to 2025.
- This data is from Acurx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: -$4.12 million | Q3 2024: -$2.83 million | Q2 2025: -$2.27 million | Q3 2025: -$2.03 million.
- Historical annual values: Fiscal year 2025: -$8.09 million | Fiscal year 2024: -$14.12 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: